Pharmaxis Skin Scarring Study Fully Recruited
21st
Dec 22
Release Date: 21/12/2022 10:14am
- Recruitment in the final placebo controlled phase of the study of 42 patients has completed
- Results expected in Q2 2023 to assess safety profile, improvements in scar appearance and function, and evidence that LOX inhibition is modifying scar tissue at a structural and biochemical level.
Categories: News and Media